persmedРоссийский журнал персонализированной медициныRussian Journal for Personalized Medicine2782-38062782-3814ФОНД АЛМАЗОВА10.18705/2782-3806-2022-2-4-97-102persmed-72Research ArticleКЛИНИЧЕСКИЕ СЛУЧАИCLINICAL CASEИндивидуальный подход в лечении пролактиномы у пациентки с синдромом множественной эндокринной неоплазии 1 типаIndividual approach in the treatment of prolactinoma in a patient with multiple endocrine neoplasia type 1 syndromeКравчукЕ. Н.KravchukE. N.

Кравчук Екатерина Никодимовна, кандидат медицинских наук, старший научный сотрудник НИЛ нейроэндокринных опухолей НИЦ персонализированной онкологии

ул. Аккуратова, д. 2, Санкт-Петербург, 197341

 

Kravchuk Ekaterina N., MD, PhD, senior researcher of the Laboratory of Neuroendocrine Tumors in the Research Centre of Personalized Oncology

Akkuratova str., 2, Saint Petersburg, 197341

 

kravchuke@gmail.comЦойУ. А.TsoyU. A.

Цой Ульяна Александровна, кандидат медицинских наук, заведующий НИЛ нейроэндокринных опухолей НИЦ персонализированной онкологии

Санкт-Петербург

 

Tsoy Uliana A., MD, PhD, Head of the Laboratory of Neuroendocrine Tumors in the Research Centre of Personalized Oncology

Saint Petersburg

СередаС. В.SeredaS. V.

Середа Светлана Сергеевна, врач-эндокринолог

Санкт-Петербург

Sereda Svetlana S., MD, endocrinologist

Saint Petersburg

ГриневаЕ. Н.GrinevaE. N.

Гринева Елена Николаевна, доктор медицинских наук, профессор, директор Института эндокринологии

Санкт-Петербург

Grineva Elena N., MD, PhD, professor, Director of the Institute of endocrinology

Saint Petersburg

Федеральное государственное бюджетное учреждение «Национальный медицинский исследовательский центр имени В. А. Алмазова» Министерства здравоохранения Российской Федерации, Научный центр мирового уровня «Центр персонализированной медицины»РоссияAlmazov National Medical Research Centre, World-Class Research Centre for Personalized MedicineRussian FederationСанкт-Петербургское государственное бюджетное учреждение здравоохранения «Центр планирования семьи и репродукции»РоссияFamily Planning and Reproduction CenterRussian Federation2022160920222497102Copyright © Кравчук Е.Н., Цой У.А., Середа С.В., Гринева Е.Н., 20222022Кравчук Е.Н., Цой У.А., Середа С.В., Гринева Е.Н.Kravchuk E.N., Tsoy U.A., Sereda S.V., Grineva E.N.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://persmed.elpub.ru/jour/article/view/72

Пролактинома и связанная с ней гиперпролактинемия являются одной из основных причин бесплодия. Заболевание может развиваться в рамках синдрома множественной эндокринной неоплазии 1 типа (МЭН1), и ведение таких пациентов может отличаться от лечения спорадических форм. В статье представлен клинический случай планировавшей беременность пациентки с пролактиномой, которая развилась в рамках синдрома МЭН1. Продемонстрирован индивидуальный подход в выборе лечебной тактики, позволивший решить задачу восстановления фертильности.

Prolactinoma and associated hyperprolactinemia is one of the main causes of infertility. The disease can develop within the framework of multiple endocrine neoplasia type 1 (MEN 1), and the management of such patients may differ from the treatment of sporadic forms. The article presents a clinical case of a patient with prolactinoma that developed as part of MEN1 syndrome who planned pregnancy. An individual approach to the choice of therapeutic tactics was demonstrated, which allowed solving the problem of restoring fertility.

 

беременностьгиперпролактинемиякаберголинМЭН1нейрохирургияпролактиномаcabergolinehyperprolactinaemiaMEN1neurosurgerypregnancyprolactinomaФинансирование / Funding Работа выполнена при финансовой поддержке Министерства науки и высшего образования Российской Федерации (Соглашение № 075-15- 2022-301 от 20.04.2022)The work was carried out with the financial support of the Ministry of Science and Higher Education of the Russian Federation (Agreement No. № 075-15-2022-301, 20.04.2022)ReferencesMaiter D, Primeau V. 2012 update in the treatment of prolactinomas. Ann Endocrinol. 2012;73:90–8.Maiter D, Primeau V. 2012 update in the treatment of prolactinomas. Ann Endocrinol. 2012;73:90–8.Melmed S, Casanueva FF, Hoffman AR, et al. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96:273–88.Melmed S, Casanueva FF, Hoffman AR, et al. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96:273–88.Molitch ME. Endocrinology in pregnancy: management of the pregnant patient with a prolactinoma. Eur J Endocrinol. 2015;172:R205–13.Molitch ME. Endocrinology in pregnancy: management of the pregnant patient with a prolactinoma. Eur J Endocrinol. 2015;172:R205–13.Мельниченко Г.А., Дзеранова Л.К., Пигарова Е.А., Воротникова С.Ю., Рожинская Л.Я., Дедов И.И. Федеральные клинические рекомендации по клинике, диагностике, дифференциальной диагностике и методам лечения гиперпролактинемии. Проблемы эндокринологии. 2013;59(6):19–26.Melnichenko GA, Dzeranova LK, Pigarova EA, Vorotnikova SIu, Rozhinskaia LIa, Dedov II. Problemy Endokrinologii. 2013;59(6):19–26. In RussianAkkus G, Karagun B, Yaldız HN, et al. Outcomes of surgical and/or medical treatment in patients with prolactinomas during long-term follow-up: a retrospective single-centre study. Horm Mol Biol Clin Investig. 2020;17;42(2):153–157.Akkus G, Karagun B, Yaldız HN, et al. Outcomes of surgical and/or medical treatment in patients with prolactinomas during long-term follow-up: a retrospective single-centre study. Horm Mol Biol Clin Investig. 2020;17;42(2):153–157.Giusti F, Cianferotti L, Boaretto F, et al. Multiple endocrine neoplasia syndrome type 1: institution, management, and data analysis of a nationwide multicenter patient database. Endocrine. 2017;58(2):349–359.Giusti F, Cianferotti L, Boaretto F, et al. Multiple endocrine neoplasia syndrome type 1: institution, management, and data analysis of a nationwide multicenter patient database. Endocrine. 2017;58(2):349–359.Brandi ML, Agarwal SK, Perrier ND, et al. Multiple Endocrine Neoplasia Type 1: Latest Insights. Endocr Rev. 2021;42(2):133–170.Brandi ML, Agarwal SK, Perrier ND, et al. Multiple Endocrine Neoplasia Type 1: Latest Insights. Endocr Rev. 2021;42(2):133–170.Dreijerink KM, Goudet P, Burgess JR, et al. Breast-cancer predisposition in multiple endocrine neoplasia type 1. N Engl J Med. 2014;371(6):583–584.Dreijerink KM, Goudet P, Burgess JR, et al. Breast-cancer predisposition in multiple endocrine neoplasia type 1. N Engl J Med. 2014;371(6):583–584.Tepede AA, Welch J, Lee M, et al. 18F-FDOPA PET/CT accurately identifies MEN1-associated pheochromocytoma. Endocrinol Diab Metab. 2020;2020:19-0156.Tepede AA, Welch J, Lee M, et al. 18F-FDOPA PET/CT accurately identifies MEN1-associated pheochromocytoma. Endocrinol Diab Metab. 2020;2020:19-0156.Trouillas J, Labat-Moleur F, Sturm N, et al. Pituitary tumors and hyperplasia in multiple endocrine neoplasia type 1 syndrome (MEN1): a case-control study in a series of 77 patients versus 2509 non-MEN1 patients. Am J Surg Pathol. 2008;32(4):534–43.Trouillas J, Labat-Moleur F, Sturm N, et al. Pituitary tumors and hyperplasia in multiple endocrine neoplasia type 1 syndrome (MEN1): a case-control study in a series of 77 patients versus 2509 non-MEN1 patients. Am J Surg Pathol. 2008;32(4):534–43.Valea A, Sandru F, Petca A, et al. Aggressive prolactinoma. Exp Ther Med. 2022;23(1):74.Valea A, Sandru F, Petca A, et al. Aggressive prolactinoma. Exp Ther Med. 2022;23(1):74.Goudet P, Murat A, Binquet C, et al. Risk factors and causes of death in MEN1 disease. A GTE (Groupe d’Etude des Tumeurs Endocrines) cohort study among 758 patients. World J Surg. 2010;34(2):249–255.Goudet P, Murat A, Binquet C, et al. Risk factors and causes of death in MEN1 disease. A GTE (Groupe d’Etude des Tumeurs Endocrines) cohort study among 758 patients. World J Surg. 2010;34(2):249–255.Goudet P, Dalac A, Le Bras M, et al. MEN1 disease occurring before 21 years old: a 160-patient cohort study from the Groupe d’étude des Tumeurs Endocrines. J Clin Endocrinol Metab. 2015;100(4):1568-1577.Goudet P, Dalac A, Le Bras M, et al. MEN1 disease occurring before 21 years old: a 160-patient cohort study from the Groupe d’étude des Tumeurs Endocrines. J Clin Endocrinol Metab. 2015;100(4):1568-1577.Vannucci L, Marini F, Giusti F, et al. MEN1 in children and adolescents: Data from patients of a regional referral center for hereditary endocrine tumors. Endocrine. 2018 Feb;59(2):438–448.Vannucci L, Marini F, Giusti F, et al. MEN1 in children and adolescents: Data from patients of a regional referral center for hereditary endocrine tumors. Endocrine. 2018 Feb;59(2):438–448.Daglar HK, Kirbas A, Biberoglu E, et al. Management of a multiple endocrine neoplasia type 1 during pregnancy: a case report and review of the literature. J Exp Ther Oncol. 2016;11(3):217–220.Daglar HK, Kirbas A, Biberoglu E, et al. Management of a multiple endocrine neoplasia type 1 during pregnancy: a case report and review of the literature. J Exp Ther Oncol. 2016;11(3):217–220.Mistry M, Gupta M, Kaler M. Pregnancy in multiple endocrine neoplasia type 1 equals multiple complications. Obstet Med. 2014;7(3):123–125.Mistry M, Gupta M, Kaler M. Pregnancy in multiple endocrine neoplasia type 1 equals multiple complications. Obstet Med. 2014;7(3):123–125.Thakker RV, Newey PJ, Walls GV, et al. Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1). J Clin Endocrinol Metab. 2012;97(9):2990– 3011.Thakker RV, Newey PJ, Walls GV, et al. Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1). J Clin Endocrinol Metab. 2012;97(9):2990– 3011.Stratakis CA, Tichomirowa MA, Boikos S, et al. The role of germline AIP, MEN1, PRKAR1A, CDKN1B and CDKN2C mutations in causing pituitary adenomas in a large cohort of children, adolescents, and patients with genetic syndromes. Clin Genet. 2010;78(5):457–463.Stratakis CA, Tichomirowa MA, Boikos S, et al. The role of germline AIP, MEN1, PRKAR1A, CDKN1B and CDKN2C mutations in causing pituitary adenomas in a large cohort of children, adolescents, and patients with genetic syndromes. Clin Genet. 2010;78(5):457–463.Salenave S, Ancelle D, Bahougne T, et al. Macroprolactinomas in children and adolescents: factors associated with the response to treatment in 77 patients. J Clin Endocrinol Metab. 2015;100(3):1177– 1186.Salenave S, Ancelle D, Bahougne T, et al. Macroprolactinomas in children and adolescents: factors associated with the response to treatment in 77 patients. J Clin Endocrinol Metab. 2015;100(3):1177– 1186.Park K, Park KH, Park HR, et al. Long-term Outcome of Microscopic Transsphenoidal Surgery for Prolactinomas as an Alternative to Dopamine Agonists. J Korean Med Sci. 2021;36(15):e97.Park K, Park KH, Park HR, et al. Long-term Outcome of Microscopic Transsphenoidal Surgery for Prolactinomas as an Alternative to Dopamine Agonists. J Korean Med Sci. 2021;36(15):e97.Zamanipoor Najafabadi AH, Zandbergen IM, de Vries F, et al. Surgery as a Viable Alternative FirstLine Treatment for Prolactinoma Patients. A Systematic Review and Meta-Analysis. J Clin Endocrinol Metab. 2020;105(3):e32–41.Zamanipoor Najafabadi AH, Zandbergen IM, de Vries F, et al. Surgery as a Viable Alternative FirstLine Treatment for Prolactinoma Patients. A Systematic Review and Meta-Analysis. J Clin Endocrinol Metab. 2020;105(3):e32–41.Maiter D. Prolactinoma and pregnancy: From the wish of conception to lactation. Ann Endocrinol (Paris). 2016;77(2):128–34.Maiter D. Prolactinoma and pregnancy: From the wish of conception to lactation. Ann Endocrinol (Paris). 2016;77(2):128–34.

The authors declare that there are no conflicts of interest present.